Study 102 reinforces our confidence in the potentially transformative benefits of SRP9001 including among other things the fact that in the Studys prespecified analysis the participants in the 45 age group robustly achieved a statistically significant and clinically meaningful improvement in NSAA over placebo as predicted by our prior Study 101